Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) obtained overwhelming shareholder approval for every item on the agenda at its 16 June 2026 annual general meeting (AGM) and concurrent A- and H-share class meetings held in Shanghai.
Strong turnout and voting support • A total of 1,467 shareholders and proxies attended the AGM, representing 1.10 billion shares, or 41.48 % of the company’s issued share capital. • Each of the 12 ordinary and three special resolutions passed comfortably; most attracted “for” votes exceeding 99 %. • The board’s 2025 annual report, profit-distribution plan, re-appointment of Ernst & Young as domestic and international auditor for 2026, renewal of financing and guarantee limits, and mandates for debt financing and disposal of listed equity stakes were all endorsed. • Special mandates authorising the board to issue new A/H shares and to repurchase up to designated limits of both H shares and A shares passed with 94.53 %–99.95 % support across the various meetings.
Final dividend confirmed Shareholders approved a final dividend of RMB0.39 per share (pre-tax) for FY 2025, to be funded from undistributed profits: • A-shareholders will receive the payout in renminbi. • H-shareholders will receive HKD0.45 per share (pre-tax), based on the RMB/HKD average exchange rate of 0.86938 for the five business days preceding the AGM. • Record date for H-shares: 24 July 2026; register closure: 20–24 July 2026. • Dividend cheques are scheduled to be mailed on or around 14 August 2026 via CMB Wing Lung (Trustee) Limited.
Tax treatment • A 10 % withholding tax applies to H-shareholders classified as non-resident enterprises or individuals. • Mainland investors holding H shares through Shanghai- or Shenzhen-Hong Kong Stock Connect will be subject to a 20 % individual income tax on dividends, with mainland enterprise investors required to self-declare and pay applicable taxes. • Investors eligible for reduced treaty rates may apply for refunds through tax authorities after dividend distribution.
Class-meeting outcomes • At the A-shareholders’ class meeting, 45.63 % of eligible A shares were represented; repurchase mandates for both H and A shares garnered 99.61 % and 99.69 % approval, respectively. • The H-shareholders’ class meeting saw 25.39 % of H shares voted, with 99.95 % support for each repurchase mandate.
Compliance assurance Grandall Law Firm (Shanghai) confirmed that convening, procedures and voting complied with the PRC Company Law and the company’s Articles of Association. BDO Limited acted as independent scrutineer for poll counting.
With all resolutions carried, Fosun Pharma’s board now holds refreshed authorities to pursue capital-markets activities, manage financing lines and execute share repurchases, while shareholders will receive a total cash return of approximately RMB1.04 billion based on the declared final dividend.
Comments